Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 6;168(5):317-325.
doi: 10.7326/M17-0028. Epub 2018 Jan 16.

Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study

Malin Hultcrantz  1 , Magnus Björkholm  2 , Paul W Dickman  3 , Ola Landgren  4 , Åsa R Derolf  2 , Sigurdur Y Kristinsson  5 , Therese M L Andersson  3
Affiliations

Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study

Malin Hultcrantz et al. Ann Intern Med. .

Abstract

Background: Patients with myeloproliferative neoplasms (MPNs) are reported to be at increased risk for thrombotic events. However, no population-based study has estimated this excess risk compared with matched control participants.

Objective: To assess risk for arterial and venous thrombosis in patients with MPNs compared with matched control participants.

Design: Matched cohort study.

Setting: Population-based setting in Sweden from 1987 to 2009, with follow-up to 2010.

Patients: 9429 patients with MPNs and 35 820 matched control participants.

Measurements: The primary outcomes were rates of arterial and venous thrombosis. Flexible parametric models were used to calculate hazard ratios (HRs) and cumulative incidence with 95% CIs.

Results: The HRs for arterial thrombosis among patients with MPNs compared with control participants at 3 months, 1 year, and 5 years were 3.0 (95% CI, 2.7 to 3.4), 2.0 (CI, 1.8 to 2.2), and 1.5 (CI, 1.4 to 1.6), respectively. The corresponding HRs for venous thrombosis were 9.7 (CI, 7.8 to 12.0), 4.7 (CI, 4.0 to 5.4), and 3.2 (CI, 2.9 to 3.6). The rate was significantly elevated across all age groups and was similar among MPN subtypes. The 5-year cumulative incidence of thrombosis in patients with MPNs showed an initial rapid increase followed by gentler increases during follow-up. The HR for venous thrombosis decreased during more recent calendar periods.

Limitation: No information on individual laboratory results or treatment.

Conclusion: Patients with MPNs across all age groups have a significantly increased rate of arterial and venous thrombosis compared with matched control participants, with the highest rates at and shortly after diagnosis. Decreases in the rate of venous thrombosis over time likely reflect advances in clinical management.

Primary funding source: The Cancer Research Foundations of Radiumhemmet, Blodcancerfonden, the Swedish Research Council, the regional agreement on medical training and clinical research between Stockholm County Council and Karolinska Institutet, the Adolf H. Lundin Charitable Foundation, and Memorial Sloan Kettering Cancer Center.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Arterial (A) and venous (B) thrombosis in MPN patients vs matched controls during follow-up
Figure 2.
Figure 2.
Arterial (A) and venous (B) thrombosis during follow-up in MPN patients vs matched controls in relation to calendar period of diagnosis
Figure 2.
Figure 2.
Arterial (A) and venous (B) thrombosis during follow-up in MPN patients vs matched controls in relation to calendar period of diagnosis
Figure 3.
Figure 3.
Cumulative incidence of arterial and venous thrombosis in relation to age at diagnosis and sex
Figure 3.
Figure 3.
Cumulative incidence of arterial and venous thrombosis in relation to age at diagnosis and sex
Figure 3.
Figure 3.
Cumulative incidence of arterial and venous thrombosis in relation to age at diagnosis and sex
See this image and copyright information in PMC

Comment in

References

    1. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779–90. - PubMed
    1. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–8. - PubMed
    1. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054–61. - PubMed
    1. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387–97. - PubMed
    1. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3(7):e270. - PMC - PubMed

Publication types